NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...
Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2 nd Line efficacy evaluable population of 12 months (n=9) Median OS of Intent to Treat population (1L ...
The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival (OS) rate of 77%, with no increase in toxicity compared to treatment without ...
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma To our knowledge, this is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback